GB2226002A - Stabilisation process for hydrated lipid lamellar phases - Google Patents

Description

2 liposomes, in particular the utilization of a gel form in a hydrocolloid

(C.A., volume 97, 1982, 188 156K referring to an article published in J. Pharm. Pharmacol., 1982, 34 (7, 473-4); see also the document WO 85/03640, in which a large number of substances are described which can be used as gelling agents, in particular carbohydrates such as the celluloses, gums in particular carrageenin, xanthan, collagen, polvacrylamide, polysiloxanes, polymers of aminoacids such as gelatinized albumin, gelatin (page 12, lines 23 to 34).

The utilization of a gel presents many disadvantages. First of all, it seriously complicates the preparation of the compositions, in particular pharmaceutical or cosmetic compositions. In fact, the utilization of a gel poses serious handling problems on account of the physical properties of the gel, and in particular their non-pourable character. Finally, a problem relating more particularly to the use of collagen as gel support is that collagen exhibits a certain antigenicityeven though it is low. Again in the case of collagen, acid-soluble collagen is usually used.

0 Now the composition must have a pH close to neutrality from the point of view of the stability of the liposomes as well as one close to the physiological pF in the case when it is used in beauty care, but these ae pH conditions under which the acid-soluble collagen precipitates and zhe inclusion of liposomes becomes impossible. This phenomenon can be prevented by very complicated and expensive conditions which cannot be applied on an industrial scale and which include conditions of low temperature close to CC. This means that industrial production at low cost cannot be conteMD1ated.

Thus, the aim of the present invention is to resolve the new technical problem consisting of. providing a solution which makes it possible to stabilize the hydrated lipid lamellar phases, in particular liposomes, with the aid of a stabilizing Support which is available in the form of a sufficiently fluid solution to eliminate all of the disadvantages inherent in the use of stabilizing supports in the form of a gel.

Another aim of the present invention is to resolve the new technical problem consisting of supplying a solution which makes it possible to stabilize the hydrated lipid lamellar phases, in particular liposomes, 11 k 3 - by the use of a sufficiently fluid stabilizing support which is devoid of antigenicity and which, in addition, requires only the implementation of an extremely simple procedure, applicable industrially under simple operating conditions, and which can be varied relatively widely to give rise to a practically perfect reproducibility.

Another aim of the present invention is to resolve the new technical problem consiting of providing a solution which enables the hydrated lipid lamellar phases, in particular liposomes, to be stallized by the use of a stabilizing support compatible with the formation of emulsions.

All of these technical problems are resolved for the first time by the present invention in a satisfactory manner which can be used industrially.

In accordance with one aspect of the present invention, therefore, there is provided a stabilizaton process for hydrated 11pid lamellar phases, for example liposomes, which comprises the introduction of the said hydra ted lipid lamellar phase into a stabilizing support, characterized in that the said stabilizing support is prepared in the following manner:

(a) a solution of atelocollagen and a solution of glycosamino glycans are prepared separately; then (b) the said solution of atelocollagen is mixed with the solution of glycosaminoglycans.

According to a preferred procedure, the mixture is prepared by intro ducing the solution of glycosaminoglycans into the solution of atelocollagen.

Preferably, also, the solution of glycosaminoglycans is prepared by dissolving the glycosaminoglycan in a basic aqueous solution, preferably an aqueous- solution of sodium hydroxide, the pH of which is such that after mixing with the solution of atelocollagen, the pH of the mixture constituting the stabilizing support remains slightly basic while being close to neutrality.

Preferably, the final pH is close to 8.

According to another advantageous featureg the concentration i::

4 1P of glycosaminoglycan in the solution of glycosaminoglycans varies from 0. 5 to 4%, and more especially from 0.5 to 2% and preferably is close to 1%.

According to another feature of the process of the invention, the solution of atelocollagen is an aqueous solution of atelocollagen, preferably having a concentration varying between 0.5 and 2% by weight, and more preferably close to 1%. This solution of atelocollagen can be prepared according to the invention by the dissolution of fibres of atelocollagen in a slightly acidic aqueous solution.

According to a particular embodiment of the invention, these fibres of atelocollagen are dissolved in 0.1 M acetic acid.

According to another particular embodiment of the process according to the invention, the atelocollagen is produced by enzymatic digestion of collagen.

According to another special feature of the process according to the invention, the hydrated lipid lamellar phases, for example liposomes, are introduced into the solution of the stabilizing support according to the invention, the volumes of the two components being approximately equal.

According to a particular embodiment of the invention, the proportion of the lipid lamellar phases, for example liposomes, represents about 1% of the final composition.

According to a second feature, the present invention also provides a composition containing hydrated lipid lamellar phases, for example liposomes, stabilized by the presence of a stabilizing support, characterized in that the stabilizing support is in the form of a solution containing a mixture of atelocollagen and glycosaminoglycans.

According to a variant of a particular embodiment of the invention, the glycosaminoglycans used are chosen from among the structural glycosaminoglycans, in particular hyaluronic acid, chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, heparan sulfate, keratan sulfate; all the secretory glycosaminoglycans, in particular heparin and its derivatives as well as the mucoitin sulfates..

Z k is According to another feature of the composition according to the invention, this latter relates to the starting solutions of atelocollagen and glycosaminoglycans for the preparation of the solution of the mixture, the properties of which have been set out previously in the process.

The relative proportion of glycosaminoglycans with respect to the atelocollagen lies preferably between 18 and 25% by weight of the atelocollagen.

According to another property of the composition according to the invention, the solution of the stabilizing support has a pH which is slightly basic but close to neutrality, and is preferably of the order of 8.

According to another property of the composition according to the invention, this composition is produced by mixing approximately equal volumes of solutions of hydrated lipid lamellar phases, for example liposomes, and solutions of the stabilizing support.

A preferred utilization of the compositions according to the invention relates to a utilization in pharmacy or beauty care, in the form of pharmaceutical or cosmetic compositions. For this purpose, the composition may be used as such or after the addition of various components or appropriate excipients well known to the person skilled in the art without any Special problem, provided it is established that this addition does not modify the stability of the hydrated lipid lamellar phases, in particular the liposomes.

In a totally unexpected manner, the invention leads to a diminution of the antigenicity of the stabilizing Support.

In addition, the preparation provides a marked improvement in the protection of one of the components of the stabilizing support, namely the atelocollagen towards collagenases which leads to a prolongation "in vivo" of the retarding effect of atelocollagen.

This stabilizing support exhibits an enhanced hydrating capacity and shows a more marked regenerative action on the dermis and the epidermis by increase of cellular development.

6 -25 Another particularly unexpected advantage and one of decisive importance from the point of view of industrial exploitation lies in the fact that the atelocollagen used in the form of a solution according to the present invention is mixed in an extremely SiMDle manner with the glycosaminoglycans, thus leading to a simplification of the stabilization process and hence of the process for the manufacture of the compositions, whether for therapeutic or cosmetic use. This support is Compatible with the formation of emulsions.

Furthermore, the use of a stabilizing support in the form of a solution gives rise to a very advantageous pourable character as will be readily appreciated by the person skilled in the art.

It can thus be seen that the invention provides decisive and remarkable improvements compared with the prior art.

Other aims, properties and advantages of the invention will also become clearly appearant in the light of the explanatory description which follows and which makes reference to several examples of the preparation of Compositions according to the invention by implementing the process according to the invention described earlier.

ExaMD1e 1 PreDaration of a liposomal COMD0sition within an atelocollagenglvcosaminoelycan suDDort a) PreDaration of large multilamellar vesicles (M.L.V.) Soy-bean lecithin is dissolved in chloroform and then deposited in the form of a thin film on the walls of a glass flask by evaporation of the solvent in a vacuum. Water heated to 80'C is then poured into the flask and maintained at this temperature for 10 minutes while being stirred with a Vortex mixer. The volume of water used is such that the final mixture contains li'.o of lecithin. The contents of the flask are then left to cool to room temperature. The solution thus contains 1% of phospholipid in the form of MU liposomes.

If a water-soluble substance is to be encapsulated, it should be dissolved in the water added during the preparation.

i 7 In the case in which a lipophilic substance is to be introduced into the membrane, it should be incorporated into the chloroform phase containing the phospholipid. b) Preparation of uncross-linked collagen or atelocollagen The skin of freshly slaughtered calves is subjected to a chemical treatment for the reinoval of hair in a bath containing 3% of sodium sulfide and 4% of lime, the proportion being 100 g of skin for 3 200 cm of solution. The dermis is then isolated from the rest of the skin by a stripping operation using a rotating band saw.

The tissue obtained is ground and extruded through a grid containing 4 mm. holes. The ground preparation is then placed in contact with saturated lime water in the proportion of 1 kg for 4 1 of solution for 3 weeks. The skin thus treated is separated from the supernatant by continuous centrifugation at an acceleration of 2000 g in a centrifuge rotating at 4000 rev/min. The pellet is then washed twice with tap water with gentle stirring in a stainless steel tank at a dilution of 1 kg of pellet per 4 1 of water. The ground preparation is then subjected to two treatments with phosphate buffer pH 7.8 (21.7 g/1 of Na 2 HPO 4 and 0.78 g/l of KH 2PO4) under the same conditions as those for the water washings.The pellet is then washed in two baths of deionized and sterile water. The ground preparation obtained is placed in a solution of acetic acid (0.5 g/l, pH 3.4) at a dilution of 1 kg for 20 1 of solution. After being stirred for 5 minutes, the supernatant is separated from the pellet by continuous decantation according to the previously described technique. The collagen is then precipitated from the supernatant by the addition of dry sodium chloride to give a final concentration of about 10%. After decantation of the supernatant under gravity, the fibres obtained are dialyzed against deionized and sterile water with the aid of dialysis membranes, preferably made from dialysis tubing, the cut-off point of which lies between 6000 and 8000 daltons. After a check has been made by means of silver nitrate that the dialyzed fibres no longer contain sodium chloride, they are dissolved in a bath containing 6 g/l of acetic acid so as to give a final concentration of 1% of protein.

8 is The mixture is stirred gently for 24 hours. c) Preparation of chondroitin 4-sulfate Calf nasal septa, from which muscle and adipose tissue have been removed, are minced and ground by extrusion through a grid containing 4 mm holes; the mince is then placed for 24 hours at a temperature of 6C in potassium chloride buffer (11.8 g/l of KCL, 78.8 mg/1 of cysteine, EDTA 180 mg/1) containing 1% "MERCK" papain in the proportion of 130 g of mince for 1 1 of buffer.

The supernatant is separated from the pellet by continuous centrifugation using a centrifuge rotating at 4000 rev/min. 40 g/1 of trichloroacetic acid are then added to the supernatant. The precipitate is removed by continuous centrifugation using the technique just described. The supernatant is neutralized with sodium hydroxide pellets. The mixture is then dialyzed against deionized and sterile water with the aid of dialysis tubing, the cut-off point of which lies between 6000 and 8000 daltons. The dialyzed solution is lyophilized. Chondroitin 4-sulfate is obtained in the dry state. d) Preparation of the atelocollagen-chondroi tin 4-sulfate mixture The mucopolysaccharide is dissolved in a bath containing sodium hydroxide to give a 1% solution. This solution is added to a a gently stirred solution of atelocollagen containing 1% of protein and in the proportion of 250 ml of solution for 1 1 of coliagen solution. The amount of sodium hydroxide is such that the final pH is 8. e) Preparation of the composition lipos omes-ateloco lla gen-chondr oi tin 4-sulfate The aqueous solution of liposomes containing 2% of soy-bean lecithin is introduced into the gently stirred mixture of atelocollagenchondroitin 4- sulfate, the volumes of the two solutions being equal so that the final complex contains 1% of lecithin. ExamDle 2 PreDaration of a liposome composition in an atelocollaRen-qlvcosaminoglvcan SUDport a) Preparation of SUV liposomes (small unilamellar vesicles) Ego white lecithin is dissolved in ethanol at a concentration 0 S 9 of 30 mmol/l. The alcoholic solution is then added to a 0.15 M solution of potassium chloride. Unilamellar vesicles then form. The suspension is then dialyzed to remove the residual alcohol and may be concentrated to 2% by ultrafiltration. b) preparation of uncross-linked collagen or atelocollagen The mince of calf skin is prepared in the same manner as in the preceding example. The mince is then subjected to two treatments with phosphate buffer pH 7.8 (21.7 g/1 of NaHP04 and 0.79 g/1 of KH 2PO The treatment is conducted at a concentrati,,,!n of 1 kg of mince per 1 1 of solution. After each treatment,the residue is recovered by continuous centrifugation using a centrifuge rotating at 4000 rev/min. and giving rise to an acceleration of 2000 g. After washing with phosphate buffer, the mince is washed in two baths of deionized and sterile water under the same conditions as those used previously.

The mince is then placed at a concentration of 200 g/l in a solution of 0. 01 N hydrochloric acid containing 7.5% of pepsin with respect to the collagen. The mixture is left to stand for 24 hours at ambient temperature. Af ter this lapse of time, the same quantity of pepsin is again added to the bath and the mixture is left to stand under the same conditions as those previously described.

The supernatant is separated from the pellet by continuous centrifugation by means of the technique previously described. Sodium chloride is added to the supernatant to give a concentration of 10%. The fibres are isolated by means of continuous centrifugation and placed in Visking dialysis tubes (ref. 30/32). After complete removal of the sodium chloride, the fibres are dissolved in 0.1 M acetic acid so as to give a concentration of collagen of 1%. c) Preparation of dermatan sulfate Pig skin, stripped in a standard manner of the corneous layer and subcutaneous tissues, is minced and ground by extrusion through a grid containing 4 mm holes.

The mince is then washed with a chloroform-methanol mixture (in the proportion of 2/1 by volume). After evaporation of the solvent in a vacuum, the dry residue is treated in the same way as the mince 33 4 obtained from the nasal septa in example 1, and dermatan sulfate is obtained in the dry state. d) Preparation of the atelocollagen-dermatan sulfate mixture The mucopolysaccharide is dissolved in a bath containing sodiu,i hydroxide to give a 1% solution. This solution is added to a gently stirred solution of atelocollagen containing 1% of protein and in the proportion of 300 ml of solution for 1 1 of collagen solution. The amount of sodium hydroxide is such that the f inal pH is 8. e) Preparation of the liposome-atelocollagen-dermatan sulfate complex The aqueous solution of lipasomes containing 2% of egg white lecithin is introduced into the atelocollagen-dermatan sulfate mixture with gentle stirring. Since the volumes of the collagen and the liposome 0 solutions are equal, the final complex contains 1% of lecithin. ExaMDle 3 Control assay of the stability of the liDosomes in their atelocolla2englvcosaminoilvcan SUDport according to the invention The controi of the presence and quality of the liposomes is carried out bv electron microscopy. For that, the preparations prepared in conformity with examples I and 2 and containing 11'.0 of lecithin are diluted 10 fold. One drop of the diluted solution is placed on an electron microscope gr4id coated with an appropriate film, for example a film of R Formavar. Immediatelv afterwards, a drop of a 2% by weight solution of phosphotungstic acid, freshly prepared and neutralized to pH 7, is added to the same grid. The gar-4d is allowed to dry in air and examined by transmission microscopy.

The electron microscopy control shows that the liposomes maintain their shape and that they may be placed in contact with water without difficulty. The lyophilization step makes it possible, on the one hand, to preserve the complex for an unlimited period and, on the other hand, to prepare very concentrated pastes of liposomes and atelocollagen which can be injected into the organism in a very small volume.

The stability of the liposomes in the compositions according to the invention is checked by subjecting these compositions to an ultrasonic shock.

11 For that, the composition may be agitated with a homogenizer of the "Ultra-Turax" type rotating at 22,000 rev/min for times of 1, 3 and 5 minutes.

A comparison is carried out by subjecting an aqueous solution of the liposomes alone to the same conditions.

The electron microscopy of the compositions thus treated, namely the compositions according to the invention obtained in examples 1 and 2 and the comparative composition composed of an aqueous solution of the liposomes alone, brings out the fact that in aqueous solution the liposomes progressively disintegrate to give rise to disorganized membranes. On the other hand, the liposome vesicles maintain their shape within the stabilizing supports according to the invention even after treatment for 5 minutes.

The invention thus makes it possible to stabilize the liposomes while conserving the advantages inherent in the use of a solution of high fluidity, as stated earlier. Exar.Dle 4 Pharmaceutical or cosmetic COMDOsition A composition prepared as in examples I and 2 can be used as a pharmaceutical or cosmetic composition. Quite naturally, in such a case it is usually necessary to encapsulate an active ingredient in the liposomes, either in the membrane of the liposome or in the interior of the liposome depending on whether the active substance is hydrophobic or hydrophilic in nature, according to the procedure which is, moreover, cited in example 1 at the end of paragraph a) and is well known to the person skilled in the art.

Various excipients or other active components may be added as desired, provided that they 6o not destroy the stabilizing effect of the support according to the invention, as can be readily understood.

k 12 Example of a composition in an emulsified form This composition hasthe following empirical formulation, the percentages being expressed by weight:

% by weight Polyoxypropylene 15 (POP) - Stearyl alcohol 4 Sodium 2-stearoyl lactate 4 Polyoxy ethylene fatty acid ester 3 Glycerol stearate 3 Dioctonate of polypropylene glycol 2 Methyl parabenzoate 0.3 Polypropylene glycol 2 Allantoin 0.2 Carboner 940 R 0.2 Triethanolamine 0.5 "Complex" of liposomes in the atelocollagenglycosaminoglycan stabilizing support according to the invention 30 Purified water 50.8 z The preparation of this composition in emulsified form is carried out in the following manner.

First, an emulsion is prepared in purified water of all of the componentsother than the "complex" of liposomes in the atelocollagen glycosaminoglycan stabilizing support according to the invention.in a standard manner.

Once this emulsion is formed, the "complex" of liposomes in the atelocollagen-glycosaminoglycan stabilizing support according to the invention, such as that prepared according to examples 1 or 2, Vith stirring which is maintained for 1 hour, care being taken to maintain the temperature below 30'C.

In this way, a composition in emulsified form is obtained 13 in which the liposomes are stable.

This stability was checked by electron microscopy and constitutes a remarkable result of the invention.

Naturally, the present invention comprises all of the agents constituting technical equivalents of the agents described as well as their various combinations. For example, it is quite clear that the term "glycosaminoglycan" need not be interpreted strictly and that it includes the mucopolysaccharides as equivalents, given that the glycosaminoglycans are polymers constituted of disaccharide units arranged in a linear manner and usually composed of an uronic acid and a hexosamine. Thus, the mucopolysaccharides are included in the definition of the glycosaminoglycans.

Similarly, the atelocollagen must be understood as being collagen from which the telopeptides have been removed and which constitutes uncross-linked collagen as understood by the person skilled in the art.

Finally, it is to be observed that the combination according to the invention of glycosaminoglycans and atelocollagen makes it possible to prepare a stabilizing support in the form of a solution at a pH close to neutrality without precipitation of the atelocollagen being brought about. Furthermore, the support according to the invention makes it possible to prepare emulsions without difficulty; that constitutes one of the decisive technical advantages of the invention.

In addition, the glycosaminoglycans suppress almost completely the residual antigenicity of the atelocollagen.

It is also to be noted that the complete composition prepared according to the invention may be lyophilized, and this constitutes a crucial industrial advantage.

35, 14

Claims (26)

1. A process for the stabilization of a hydrated lipid lamellar phase which comprises introducing the lipid lamellar phase into a stabilizing support obtained by separately preparing a solution of atelocollagen and a solution of glycosaminoglycans and then mixing the two solutions.

2. A process according to claim 1, wherein said hydrated lipid lamellar phase comprises lipasomes.

3. A process according to claim 1 or 2, wherein, in preparing the support, the solution of glycosaminoglycans is introduced into the solution of atelocollagen.

4. A process according to claim 1, 2 or 3, wherein the solution of glycosaminoglycans is prepared by dissolving glycosaminoglycan in a basic aqueous solution, the pH of which is such that after mixing with the solution of atelocollagen the pH of the mixture remains slightly basic but close to neutrality.

5. A process according to claim 4, wherein the pH of the mixture constituting the stabilizing support is about 8.

6. A process according to claim 4, wherein the basic aqueous solution is an aqueous solution of sodium hydroxide.

7. A process according to any one of claims 1 to 6, wherein the concen tration of glycosaminoglycan in the solution of glycosaminoglycans is in the range 0.5 to 4% by weight.

8. A process according to claim 7, wherein the concentration of glycosaminoglycan in the solution of glycosaminoglycans is about 1% by weight.

9. A process according to any one of claims 1 to 8, wherein the solution of atelocallagen is an aqueous solution of atelocallagen having a concentra- tion in the range 0.5 to 2% by weight.

Y 1

10. A process according to claim 9, wherein the solution of atelocollagen is an aqueous solution having a concentration of 1% by weight.

11. A process according to any one of claims 1 to 10, wherein the atelo collagen solution is prepared by dissolving atelocollagen fibres in a slightly acidic aqueous solution.

12. A process according to claim 11, wherein the slightly acidic aqueous solution is 0.1 M acetic acid.

13. A process according to any one of claims 1 to 11, wherein the atelocollagen is obtained by enzymatic digestion of collagen.

14. A process according to any one of claims 1 to 13 wherein the two solutions are mixed in approximately equal volumes.

15. A process according to any one of claims 1 to 14, wherein the proportion of the lipid lamellar phase incorporated into the support represents about 1% of the final composition.

16. A composition containing a hydrated lipid lamellar phase, wherein the lipid lamellar phase is incorporated in a stabilizing support comprising a solution containing a mixture of atelocollagen and glycosaminoglycans.

17. A composition according to claim 16, wherein the glycosaminoglycan is hyaluronic acid, chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, or a secretory glycosaminoglycan.

18. A composition according to claim 17, wherein the secretory glycos aminaglycan is heparin or a derivative thereof, or mucoltin sulfate.

19. A composition according to claims 16, 17 or 18, wherein the proportion of glycosaminoglycan relative to atelocollagen is in the range 18 to 25% by weight.

16

20. A composition according to any one of claims 16 to 19, wherein the stabilizing support solution has a slightly basic pH close to neutrality.

1

21.. A composition according to claim 19, wherein the stabilizing support solution has a pH of about 8.

22. A composition according to any one of claims 16 to 21, wherein the composition is obtained by mixing approximately equal volumes of a solution of hydrated lipid lamellar phase with a solution of the stabilizing support.

23. A composition according to any one of claims 16 to 22, which has been Iyophilized.

24. A stabilized composition obtained by a process according to any one of claims 1 to 15.

25. A pharmaceutical or cosmetic composition comprising the composition according to claim 24.

26. A pharmceutical or cosmetic composition comprising a composition according to any one of claims 16 to 23.

PdWisbtdI990 at The Patent Office, State House, 65J71 High Holbom.London WC1R 4TP. Further copies maybe obtained from The Patent Office. Sales Branch, St Mary Cray. Orpington. Kent BR5 3RD. Printed by Multiplex Techniques itd, St Mary Cray, Kent,. Con. 1187